{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:11:30Z","timestamp":1779275490236,"version":"3.51.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Zhejiang Natural Science Foundation Exploration Project","award":["LY24H270010"],"award-info":[{"award-number":["LY24H270010"]}]},{"name":"Key Specialized Departments of Zhejiang Province during the 13th Five-Year Plan","award":["NO. 135ZDK2019ZLK"],"award-info":[{"award-number":["NO. 135ZDK2019ZLK"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ovarian metastasis from anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma is exceedingly rare. Reporting such cases is vital for understanding its clinical management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 49-year-old woman presented with a 10-day history of amenorrhea and lower abdominal pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Imaging revealed bilateral ovarian masses and liver nodules. Liver biopsy and genetic testing confirmed the diagnosis of stage IV EML4-ALK fusion-positive lung adenocarcinoma with ovarian and hepatic metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>First-line treatment with the third-generation ALK inhibitor lorlatinib (100\u2009mg, once daily) was initiated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient achieved a partial response with significant lesion regression and normalized tumor markers, sustained for over 12 months. No severe adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case underscores the importance of molecular profiling in diagnosing metastatic tumors and confirms lorlatinib as a highly effective first-line therapy for ALK-positive non-small cell lung cancer with atypical metastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045222","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:00:48Z","timestamp":1763571648000},"page":"e45222","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["First case report of lorlatinib in the treatment of ALK-fusion-positive lung adenocarcinoma with ovarian metastasis: Clinicopathological and molecular characterization"],"prefix":"10.1097","volume":"104","author":[{"given":"Tianxiang","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Oncology, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephropathy, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keding","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Scientific Research, Zhejiang Chinese Medical University, Hangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-4450","authenticated-orcid":false,"given":"Jue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260520","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260520","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12885-016-2169-5","article-title":"Distribution and prognosis of uncommon metastases from non-small cell lung cancer.","volume":"16","author":"Niu","year":"2016","journal-title":"BMC Cancer"},{"key":"R3-20260520","first-page":"434","article-title":"[EML4-ALK fusion gene in patients with lung carcinoma: biology, diagnostics and targeted therapy].","volume":"25","author":"Va\u0161\u00edkov\u00e1","year":"2012","journal-title":"Klinicka Onkologie"},{"key":"R4-20260520","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajog.2016.01.007","article-title":"Predicting the risk of malignancy in adnexal masses based on the simple rules from the international ovarian tumor analysis group.","volume":"214","author":"Timmerman","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20260520","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13000-019-0864-7","article-title":"ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma.","volume":"14","author":"Bi","year":"2019","journal-title":"Diagn Pathol"},{"key":"R6-20260520","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/01.pas.0000166363.76082.a0","article-title":"Lung carcinoma metastatic to the ovary: a clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis.","volume":"29","author":"Irving","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R7-20260520","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13048-024-01382-8","article-title":"Mucin-producing tumors of the ovary\u2014\u2014preoperative differentiation between metastatic ovarian mucinous carcinoma and primary mucinous malignant tumors.","volume":"17","author":"Cai","year":"2024","journal-title":"J Ovarian Res"},{"key":"R8-20260520","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/00000478-200307000-00014","article-title":"Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis.","volume":"27","author":"Seidman","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R9-20260520","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2005.10.008","article-title":"Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality.","volume":"101","author":"Khunamornpong","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R10-20260520","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/modpathol.3880175","article-title":"Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.","volume":"13","author":"Chu","year":"2000","journal-title":"Modern Pathol"},{"key":"R11-20260520","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.21037\/tcr-22-273","article-title":"Ovarian metastases from ALK-positive lung adenocarcinoma: a case report and review of the literature.","volume":"11","author":"Li","year":"2022","journal-title":"Transl Cancer Res"},{"key":"R12-20260520","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III crown study.","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"R13-20260520","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers.","volume":"13","author":"Drilon","year":"2018","journal-title":"J Thor Oncol"},{"key":"R14-20260520","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1471-2407-12-278","article-title":"Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients.","volume":"12","author":"Li","year":"2012","journal-title":"BMC Cancer"},{"key":"R15-20260520","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jtho.2023.07.023","article-title":"Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced NSCLC in relation to EML4::ALK variant type and ALK with or without TP53 mutations.","volume":"18","author":"Bearz","year":"2023","journal-title":"J Thor Oncol"},{"key":"R16-20260520","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.3390\/cancers14174142","article-title":"Adjuvant PD-1 and PD-L1 inhibitors and relapse-free survival in cancer patients: the MOUSEION-04 study.","volume":"14","author":"Rizzo","year":"2022","journal-title":"Cancers"},{"key":"R17-20260520","doi-asserted-by":"crossref","first-page":"28309","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis.","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:01:18Z","timestamp":1779274878000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":17,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045222","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2025-06-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}